Mirella Ezban
Novo Nordisk Park
Malov, Denmark
Malov, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Mechanism of action and impact on thrombin generation of denecimig (Mim8), emicizumab, and zemocimig (NXT007): comparative analysis using sequence-identical analogs.
Journal: Research and practice in thrombosis and haemostasis
Published: April 21, 2026
Factor VIII in vitro bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays.
Journal: Research and practice in thrombosis and haemostasis
Published: October 12, 2025
Comparative ex vivo analysis of Mim8 in thrombin generation assays triggered by activated factor XI or tissue factor.
Journal: Research and practice in thrombosis and haemostasis
Published: May 08, 2025
Factor VIII Activity and Factor VIII Inhibitors Can Be Measured Accurately in Plasma Containing Mim8 by Using Specific Chromogenic Assays.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: September 26, 2024
A next generation FVIII mimetic bispecific antibody, Mim8, the impact on non-factor VIII related haemostasis assays.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: July 06, 2023
In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays.
Journal: Journal of thrombosis and haemostasis : JTH
Published: November 18, 2022
The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation.
Journal: Journal of thrombosis and haemostasis : JTH
Published: August 26, 2022
Measuring factor VIII activity in samples from patients treated with N8-GP (Esperoct® ; turoctocog alfa pegol) during the pathfinder clinical trials programme.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: April 01, 2020
An overview of turoctocog alfa pegol (N8-GP; ESPEROCT® ) assay performance: Implications for postadministration monitoring.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: June 14, 2019
Evaluation of N8-GP Activity Using a One-Stage Clotting Assay: A Single-Center Experience.
Journal: Acta haematologica
Published: June 05, 2019
A field study evaluating the activity of N8-GP in spiked plasma samples at clinical haemostasis laboratories.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: January 29, 2019
FIXing postinfusion monitoring: Assay experiences with N9-GP (nonacog beta pegol; Refixia® ; Rebinyn® ).
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: September 26, 2018
Last Updated: 09/26/2026